Cannabidiol Treatment for Adult Patients with Drug‐Resistant Epilepsies: A Real‐World Study in a Tertiary Center
Brain and Behavior · 2024
DOI: 10.1002/brb3.70122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2024. Verfasst von Quentin Calonge und 7 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP, Epilepsy Unit, Department of Neurology, Reference Center of Rare Epilepsies, ERN-EpiCare, Pitié-Salpêtrière Hospital, Paris, France. Hauptthemen laut MEDLINE: Cannabidiol, Drug Resistant Epilepsy, Anticonvulsants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and purpose Around 30% of patients with epilepsy show drug‐resistant epilepsy (DRE). While cannabidiol has demonstrated efficacy as an adjunctive treatment in Dravet syndrome (DS), Lennox–Gastaut Syndrome (LGS), and epilepsy related to tuberous sclerosis complex (TSC), its more global effectiveness in adult patients with DRE apart from these three specific contexts needs to be clarified.
Methods
We conducted a retrospective study at the epilepsy unit of Pitié Salpêtrière Hospital. Patients initiating pharmaceutical cannabidiol treatment and followed for at least 1 year were included. Patients were categorized into “authorized” (LGS, DS, or TSC) and “off‐label” groups. Cannabidiol effectiveness and tolerance were compared between groups, and characteristics of responders (patients with >50% reduction in seizure frequency) in the off‐label group were examined.
Results
Ninety‐one patients, followed by a median duration of 24 months, were included. A total of 35.2% of the patients were in the authorized group. No significant differences were observed in responder rates between groups (31.3% vs. 35.6%, p = 0.85) and retention rates at 1 year (75.0% vs. 74.6%, p = 0.97). Sleepiness was more commonly reported in the authorized group (50.0% vs. 22.0%, p = 0.01), with no other significant differences. Among off‐label patients ( n = 59), clobazam co‐prescription was more prevalent in responders (71.4% vs. 28.9%, p = 0.002).
Conclusion
Our findings suggest that cannabidiol may benefit all adult patients with DRE, particularly those already receiving clobazam. Randomized controlled trials are warranted in off‐label patients to validate these observational findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AP-HP, Epilepsy Unit, Department of Neurology, Reference Center of Rare Epilepsies, ERN-EpiCare, Pitié-Salpêtrière Hospital, Paris, France.
- Paris Brain Institute, ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
- AP-HP, EEG Unit, Department of Neurophysiology, Pitié-Salpêtrière Hospital, Paris, France.
- Rehabilitation Unit, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
ORCID-Profile: Quentin Calonge, Sophie Dupont, Vincent Navarro
Zitieren
APA
Calonge, Q., Besnard, A., Bailly, L., Damiano, M., Pichit, P., Dupont, S., Gourfinkel-An, I., & Navarro, V. (2024). Cannabidiol Treatment for Adult Patients with Drug‐Resistant Epilepsies: A Real‐World Study in a Tertiary Center. Brain and Behavior. https://doi.org/10.1002/brb3.70122
Vancouver
Calonge Q, Besnard A, Bailly L, Damiano M, Pichit P, Dupont S, et al. Cannabidiol Treatment for Adult Patients with Drug‐Resistant Epilepsies: A Real‐World Study in a Tertiary Center. Brain and Behavior. 2024. doi:10.1002/brb3.70122
BibTeX
@article{Calonge2024,
author = {Calonge, Quentin and Besnard, Aurore and Bailly, Laurent and Damiano, Maria and Pichit, Phintip and Dupont, Sophie and Gourfinkel-An, Isabelle and Navarro, Vincent},
title = {Cannabidiol Treatment for Adult Patients with Drug‐Resistant Epilepsies: A Real‐World Study in a Tertiary Center},
journal = {Brain and Behavior},
year = {2024},
doi = {10.1002/brb3.70122}
}
EUVIMED